All the news Showing 10 of 72 articles from: HCV and coinfectionsGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Switching from efavirenz to raltegravir leads to significant improvements in fatty liver disease in people with HIV Michael Carter / 17 August 2017 Switching to raltegravir from efavirenz is associated with significant improvements in liver steatosis for HIV-positive people with non-alcoholic fatty liver disease, Spanish investigators report in the online edition of Clinical ... Glecaprevir/pibrentasvir is effective for people with HIV/HCV co-infection Liz Highleyman / 26 July 2017 AbbVie's new pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C co-infection in the EXPEDITION-2 study, according to a presentation on Monday at the 9th International AIDS Society ... Six-question risk score can identify HIV-positive gay men needing testing for acute hepatitis C Roger Pebody / 13 June 2017 Six questions can identify HIV-positive gay men who are at elevated risk of having acute (recent) hepatitis C infection and who would benefit from further testing, according to a paper ... Co-infection with HCV increases cancer risk for people with HIV Michael Carter / 28 March 2017 People with HIV and hepatitis C virus (HCV) co-infection have an increased risk of non-AIDS-defining cancers compared to people with HIV mono-infection, investigators from Spain report in the online edition of AIDS. Even ... Two-thirds of people with HIV/HCV co-infection in Southeast Asia in need of HCV therapy Michael Carter / 15 March 2017 Almost two-thirds of people with HIV/hepatitis C virus (HCV) co-infection in Asia are in need of HCV therapy with a fifth of people having cirrhosis, investigators report in the Journal of Viral ... Glecaprevir/pibrentasvir for hepatitis C can be safely administered with common antiretrovirals Liz Highleyman / 13 March 2017 AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for people with HIV/hepatitis C ... DAA therapy cures most people with HIV/HCV co-infection with decompensated cirrhosis or liver transplants Liz Highleyman / 07 March 2017 People with HIV/hepatitis C virus (HCV) co-infection with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for ... Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer? Liz Highleyman / 27 February 2017 People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular ... New hepatitis C infections among HIV-positive gay men drop by half after direct-acting antiviral roll-out in Netherlands Liz Highleyman / 17 February 2017 A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals for the treatment of hepatitis C, researchers have already seen a dramatic decline in acute ... High hepatitis C prevalence seen in Amsterdam PrEP study participants Gus Cairns / 06 February 2017 Researchers from the Dutch pre-exposure prophylaxis (PrEP) demonstration study, AmPrEP, have found an unexpectedly high rate of hepatitis C virus (HCV) infection in participants tested for it at baseline.The HCV ... ← Prev12345...8Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive